Cargando…

Correction to: Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin

Detalles Bibliográficos
Autores principales:	Sharma, Roopali, Sandrock, Christian E., Meehan, Joni, Theriault, Nicolette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886766/ https://www.ncbi.nlm.nih.gov/pubmed/33507527 http://dx.doi.org/10.1007/s40261-020-00998-0

Ejemplares similares

Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin
por: Sharma, Roopali, et al.
Publicado: (2020)

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
por: McCurdy, Sandra, et al.
Publicado: (2020)

Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections
por: Scott, L. J.
Publicado: (2020)

Correction to: Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2018)

The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model
por: Lodise, Thomas P., et al.
Publicado: (2020)

A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP)
por: Horcajada, Juan P, et al.
Publicado: (2019)

2230. Analysis of the Microbiological Data from the Delafloxacin (DLX) Phase 3 Community-acquired Bacterial Pneumonia (CABP) Trial
por: McCurdy, Sandra, et al.
Publicado: (2019)

2234. Outcomes by Age and Gender from a Global Phase 3 Study of Delafloxacin (DLX) in Community-Acquired Bacterial Pneumonia (CABP)
por: Madej, Andrzej, et al.
Publicado: (2019)

2232. A Global Phase 3 Study of Delafloxacin (DLX) Compared with Moxifloxacin (MOX) in Patients with Community-acquired Bacterial Pneumonia (CABP)
por: Salata, Robert, et al.
Publicado: (2019)

Spotlight on New Antibiotics for the Treatment of Pneumonia
por: Russo, Alessandro
Publicado: (2020)

Respiratory infections: Community-acquired pneumonia and newer microbes
por: Reynolds, H. Y.
Publicado: (1996)

Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline
por: Kocsis, Béla, et al.
Publicado: (2021)

2228. Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Patients with Diabetes: Outcomes from a Global Phase 3 Study of Delafloxacin (DLX)
por: Kaidashev, Igor, et al.
Publicado: (2019)

Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Corey, G Ralph, et al.
Publicado: (2019)

Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy
por: Donald, Bryan J, et al.
Publicado: (2017)

On Reactions with the Newer Antibiotics
por: Dalgleish, P. G.
Publicado: (1952)

Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2017)

Correction to: The Unyvero Hospital-Acquired pneumonia panel for diagnosis of secondary bacterial pneumonia in COVID-19 patients
por: Tellapragada, Chaitanya, et al.
Publicado: (2021)

Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections
por: Scott, L. J.
Publicado: (2020)

Correction to: Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia
por: Uranga, Ane, et al.
Publicado: (2021)

Correction to: COVID-19: Pulse oximeters in the spotlight
por: Michard, Frederic, et al.
Publicado: (2020)

Correction to: Multiplex polymerase chain reaction detection of Streptococcus pneumoniae and Haemophilus influenzae and their antibiotic resistance in patients with community-acquired pneumonia from southwest Iran
por: Sheikh, Ahmad Farajzadeh, et al.
Publicado: (2022)

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment
por: Hoover, Randall, et al.
Publicado: (2016)

Delafloxacin: design, development and potential place in therapy
por: Candel, Francisco Javier, et al.
Publicado: (2017)

Profile of a Novel Anionic Fluoroquinolone—Delafloxacin
por: Tulkens, Paul M, et al.
Publicado: (2019)

Updated Review on Clinically-Relevant Properties of Delafloxacin
por: Turban, Adrien, et al.
Publicado: (2023)

New and alternative approaches to tackling antibiotic resistance
por: Tillotson, Glenn S., et al.
Publicado: (2013)

Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin
por: Righi, Elda, et al.
Publicado: (2018)

In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014
por: Pfaller, M. A., et al.
Publicado: (2017)

The in vitro activity of delafloxacin and comparator agents against bacterial pathogens isolated from patients with cancer
por: Gerges, Bahgat, et al.
Publicado: (2023)

Delafloxacin-Capped Gold Nanoparticles (DFX-AuNPs): An Effective Antibacterial Nano-Formulation of Fluoroquinolone Antibiotic
por: Abu Lila, Amr Selim, et al.
Publicado: (2022)

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
por: Hoover, Randall K., et al.
Publicado: (2017)

Safety of Delafloxacin: Focus on Adverse Events of Special Interest
por: Lodise, Thomas, et al.
Publicado: (2018)

Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei
por: McCurdy, Sandra, et al.
Publicado: (2021)

Epidemiology of community acquired pneumonia
por: Manikam, Logan, et al.
Publicado: (2012)

Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Bassetti, Matteo, et al.
Publicado: (2019)

Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Giordano, Philip A, et al.
Publicado: (2019)

Community-Acquired Pneumonia, Bacterial
por: File, Thomas M.
Publicado: (2012)

Correction to: Decision Analysis: Omadacycline Relative to Moxifoxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difcile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

Study of Antibiotic Resistance Pattern in Methicillin Resistant Staphylococcus Aureus with Special Reference to Newer Antibiotic
por: Kaur, Dardi Charan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h0n8r8i4jhofotd7n64v42heai